Biotech Startups

Oneiria Therapeutics develops therapies that modulate cell dormancy to address cancer persistence, operating in the biotechnology and cancer treatment sector.

1 investor

Engaged in discovery and development of targeted small molecule therapies for cancer treatment, including selective mutant-specific PI3K inhibitors.

1 investor

1 investor

ONYA Therapeutics develops investigational pharmaceutical treatments for chronic and acute wounds, using a patented silicone-based patch that stabilises and delivers a well-characterised active compound to modulate wound exudate and restart healing. Its lead programme OTX-PP01 targets chronic wounds such as diabetic foot ulcers, with additional variants planned for battlefield trauma and cancer-related wounds.</parameter> <parameter name="founders">[{"full_name": "Thomas Hafner", "title": "CEO & Founder"}]

1 investor

Oorja Bio is a biotechnology company developing therapies focused on fibrotic disease, aiming to repair, reverse, and remodel fibrosis.

1 investor

Opal Therapeutics develops organoid models and therapies centered on female biology to improve drug discovery outcomes in women's health. The company addresses the underserved space of female-specific drug development by building human-relevant models that better capture female biological characteristics.

1 investor

Open Bionics develops 3D-printed bionic hands called the Hero Arm, designed to be affordable, functional, and aesthetically appealing alternatives to traditional prostheses. The company serves individuals with upper limb differences and limb loss, operating in the medical devices and assistive technology space.

1 investor

Open Book Extracts produces GMP and ISO certified CBD isolate products for wellness applications. The company supplies high-purity crystalline CBD powder with USDA organic, kosher, and halal certifications for formulation in dietary supplements and wellness products.

1 investor

OpenProtein.AI offers protein language models and AI infrastructure for protein engineering, covering de novo sequence design, variant effect prediction, in silico screening, and training specialized models on proprietary data. Accessible via a no-code GUI and APIs, it serves biology and computational research teams working in protein design and drug discovery.

1 investor

Open Stent Solution develops a percutaneous medical device for mitral and tricuspid valve replacement in cardiac patients ineligible for open-heart surgery. The company leverages ribbon-based valve technology to enable less invasive treatment with smaller delivery systems adaptable to various valve sizes.

1 investor

OpenBiome Foundation advances microbiome-targeted therapies for serious conditions like Clostridioides difficile through partnerships, innovation funding, and open-access research tools. The organization works to expand patient access to microbiome treatments while accelerating scientific discovery in the field.

1 investor

OpenClinica eConsent is a digital consent platform for clinical trials that enables participants to review and electronically sign informed consent forms using media-rich content on any device. It serves academic researchers, sponsors, contract research organizations (CROs), and clinical trial sites who need to streamline enrollment while maintaining regulatory compliance across decentralized, hybrid, and in-person studies.

1 investor

Open Culture builds an automated laboratory platform (Habitat) that autonomously runs cell-culture experiments — perfusing, imaging, and recording living samples — and an AI agent that plans and executes experiments from plain-language descriptions while organizing results into a queryable knowledge graph. It serves neuroscience and biology research labs, drawing on the founders' prior Braingeneers work in electrophysiology and AI.

1 investor

The page announces the launch of a new fintech arm called CapForce. No further detail about the company's core business is provided on the page.

1 investor

OPKO Health is a fully integrated healthcare company developing multispecific therapies for serious diseases including cancers and infectious diseases, and operates BioReference Laboratories, a clinical reference laboratory serving approximately 11 million patients annually in the U.S.

1 investor

1 investor

A service that recruits customers seeking orthodontic braces through social media and refers them to dental clinics. It operates across multiple prefectures in Japan, serving orthodontic dental clinics.

1 investor

Optegra operates dedicated private eye hospitals offering ophthalmic diagnostics, cataract and laser eye surgery, and aftercare delivered by NHS-trained consultant surgeons. It serves private and NHS eye-care patients, providing free video or telephone consultations and personalised treatment plans.

1 investor

Optic (referred to as Bioptic) applies AI and foundation models to biopharma research and drug discovery, combining machine learning with scientific domain expertise for R&D. The company targets the biopharma industry, aiming to distill scientific knowledge into scalable software for therapeutics development.

1 investor

Opticyte develops the VitalO₂, a preclinical-stage medical device aimed at hospitals, with an FDA De Novo pathway and Breakthrough Device Designation. The company operates in the medical device sector.

1 investor

Optinose is a specialty pharmaceutical company that develops and markets products for patients with conditions treated by ear, nose, and throat (ENT) and allergy specialists. Its lead product, XHANCE (fluticasone propionate), uses the company's patented Bi-Directional Exhalation Delivery System (EDS) to deliver medication deep into the nasal passages.

1 investor

Optobio makes the Xpress ELISA, a 48-channel automated ELISA instrument with an integrated chemiluminescence detector that delivers results in under an hour using small sample volumes. The device supports multiplexed or single-plexed assays with 18 validated tests for laboratory immunoassay applications.

1 investor

Ora-biotics develops a low-dose, sensory-neutral prebiotic fiber ingredient, upcycled from a natural food side stream, designed to be stable in capsules and acidic beverages. The ingredient targets metabolic health outcomes such as weight management and blood glucose control by feeding beneficial gut microbes, and is aimed at product formulators in the food and supplement industry.

1 investor

OraLiva develops an AI-powered, non-invasive oral cancer test designed to detect cancer early during routine dental visits, using single-cell analysis and microfluidic technologies. The company is advancing a point-of-care diagnostic device for dental networks, building on its current lab-developed platform.

1 investor